Author

H. Schuitemaker

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 10

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Research Focus:host-pathogen & immune response· 10 Organism:mouse· 4 Research Focus:drug response / drug discovery· 3 Organism:rat· 3 Assay:protein structure· 2 Organism:Arabidopsis· 1 Research Focus:benchmarking· 1

Frequent Co-Authors

F. Wegmann· 6 shared D. H. Barouch· 5 shared R. C. Zahn· 5 shared J. Custers· 4 shared J. E. M. van der Lubbe· 4 shared L. Muchene· 4 shared E. J. Snijder· 3 shared J. Sadoff· 3 shared

Activity by Year

2020-2022 · peak 5/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

F. Wegmann

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Combination Ad26.RSV.preF/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models

E. Saeland, L. van der Fits, R. Bolder, M. Heemskerk-van der Meer, J. Drijver, Y. van Polanen, C. Vaneman, L. Tettero, F. Cox, J. Serroyen, M. J. Jorgensen, J. P. M. Langedijk, H. Schuitemaker, B. Callendret, R. C. Zahn

This study shows that combining Ad26.RSV.preF and RSV preF protein vaccine components enhances humoral, cellular, and protective immunity compared to using each component alone in preclinical models.

bioRxiv · Sep 23, 2022Immunology

CD4 binding-site antibodies induced by a subtype B HIV-1 envelope trimer

A. Schorcht, T. L. G. M. van den Kerkhof, J. Torres, E. Schermer, C. LaBranche, I. Bontjer, M. Brinkkemper, N. Gulzar, A. X. Han, J. Burger, G. Ozorowski, J. Scott, H. Schuitemaker, D. Montefiori, M. van Gils, , R. W. Sanders

This study shows that immunization with native-like HIV-1 subtype B Env trimers can induce CD4bs-directed broadly neutralizing antibodies in rabbits.

bioRxiv · Mar 23, 2022 · PreprintImmunology

Immunogenicity of an Ad26-based SARS-CoV-2 Omicron Vaccine in Naïve Mice and SARS-CoV-2 Spike Pre-immune Hamsters

M. Swart, A. de Wilde, S. Schmit-Tillemans, J. Verspuij, C. Daal, Y. Choi, A. Perkasa, E. Kourkouta, I. Tahiri, M. Mulders, A. I. Gil, L. Muchene, J. Juraszek, J. Vellinga, J. Custers, , R. Zahn

This study evaluates an Ad26-based Omicron spike vaccine in mice and pre-immune hamsters, showing it induces neutralizing antibodies against Omicron and Delta variants.

bioRxiv · Mar 4, 2022 · PreprintImmunology

Ad26.COV2.S elicited neutralizing activity against Delta and other SARS-CoV-2 variants of concern

M. Jongeneelen, K. Kaszas, D. Veldman, J. Huizingh, R. van der Vlugt, T. Schouten, D. Zuijdgeest, T. Uil, G. van Roey, N. Guimera, M. Navis, R. Bos, M. Le Gars, J. Sadoff, L. Muchene, , B. Brandenburg

This study evaluates the neutralizing activity of Ad26.COV2.S vaccine sera against SARS-CoV-2 variants, finding reduced effectiveness against Beta and Gamma but less reduction against Delta.

bioRxiv · Jul 1, 2021 · PreprintImmunology

Neutralizing antibodies elicited by the Ad26.COV2.S COVID-19 vaccine show reduced activity against 501Y.V2 (B.1.351), despite protection against severe disease by this variant.

P. Moore, T. Moyo, T. Hermanus, P. Kgagudi, F. Ayres, Z. Makhado, J. Sadoff, M. Le Gars, G. van Roey, C. Crowther, N. Garrett, L.-G. Bekker, L. Morris, H. Schuitemaker, G. Gray

The study assesses neutralizing antibody activity against 501Y.V2 variant post-Ad26.COV2.S vaccination, finding reduced neutralization but potential protection via other immune mechanisms.

bioRxiv · Jun 9, 2021 · PreprintImmunology

SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques

R. Roozendaal, L. Solforosi, D. Stieh, J. Serroyen, R. Straetemans, F. Wegmann, S. K. Rosendahl Huber, J. E. M. van der Lubbe, J. Hendriks, M. le Gars, L. Dekking, D. N. Czapska-Casey, N. Guimera, S. Janssen, S. Tete, , R. Zahn

This study shows that Ad26.COV2.S vaccine provides long-lasting protection in rhesus macaques, predicted by binding and neutralizing antibody levels against SARS-CoV-2.

bioRxiv · Jan 30, 2021Immunology

Low-Dose Ad26.COV2.S Protection Against SARS-CoV-2 Challenge in Rhesus Macaques

X. He, A. Chandrashekar, R. C. Zahn, F. Wegmann, J. Yu, N. B. Mercado, K. McMahan, A. J. Martinot, C. Piedra-Mora, S. Beecy, S. Ducat, R. Chamanza, S. Rosendahl Huber, L. van der Fits, E. N. Borducchi, , D. H. Barouch

This study shows that low doses of Ad26.COV2.S vaccine protect rhesus macaques against SARS-CoV-2 challenge, with higher doses needed for upper respiratory tract protection.

bioRxiv · Jan 27, 2021Immunology

Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing

J. E. M. van der Lubbe, S. K. Rosendahl Huber, A. Vijayan, L. Dekking, E. van Huizen, J. Vreugdenhil, Y. Choi, M. R. M. Baert, K. Feddes-de Boer, A. Izquierdo Gil, M. van Heerden, T. J. Dalebout, S. K. Myeni, M. Kikkert, E. J. Snijder, , F. Wegmann

This study shows that a single dose of Ad26.COV2.S vaccine protects Syrian hamsters from G614 SARS-CoV-2 infection and prevents VAERD even with suboptimal immunity.

bioRxiv · Jan 8, 2021 · PreprintImmunology

Immunogenicity and protective efficacy of one- and two-dose regimens of the Ad26.COV2.S COVID-19 vaccine candidate in adult and aged rhesus macaques

L. Solforosi, H. Kuipers, S. K. Rosendahl Huber, J. E. M. van der Lubbe, L. Dekking, D. N. Czapska-Casey, A. Izquierdo Gil, M. Baert, J. Drijver, J. Vaneman, E. van Huizen, Y. Choi, J. Vreugdenhil, S. Kroos, A. H. de Wilde, , R. C. Zahn

This study evaluates one- and two-dose regimens of the Ad26.COV2.S vaccine in rhesus macaques, showing higher antibody responses with two doses and protection against SARS-CoV-2 in aged animals.

bioRxiv · Nov 17, 2020Immunology

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses

R. Bos, L. Rutten, J. E. M. van der Lubbe, M. J. G. Bakkers, G. Hardenberg, F. Wegmann, D. Zuijdgeest, A. H. de Wilde, A. Koornneef, A. Verwilligen, D. van Manen, T. Kwaks, R. Vogels, T. J. Dalebout, S. K. Myeni, , H. Schuitemaker

This paper evaluates a prefusion-stabilized SARS-CoV-2 Spike protein vaccine candidate, Ad26.COV2.S, showing potent neutralizing and Th1-polarized immune responses in mice.

bioRxiv · Jul 30, 2020Immunology